Source comparison
Sermorelin Body Composition Complete Guide 2026: Clinical Comparison
The following table compares sermorelin acetate against alternative peptide-based body composition protocols used in clinical research settings. Each compound operates through distinct receptor pathways with different risk-benefit profiles. Sermorelin Acetate
This comparison does not assign a generated winner or score.
- The following table compares sermorelin acetate against alternative peptide-based body composition protocols used in clinical research settings. Each compound operates through distinct receptor pathways with different risk-benefit profiles.
- Sermorelin Acetate
- GHRH receptor agonist. Stimulates endogenous GH release in pulsatile pattern
- 200–500 mcg daily SC
- 2.4–3.1 kg
- 1.7–2.2 kg
- Gold standard for physiological GH restoration with preserved negative feedback; minimal receptor downregulation compared to exogenous GH
- CJC-1295 + Ipamorelin
- DAC-modified GHRH analog + GHRP-6 analog. Sustained GH elevation + ghrelin receptor activation
- 100 mcg each, 2–3x weekly SC
- 3.2–4.1 kg
- 2.1–2.8 kg
- Greater lean mass gains than sermorelin alone due to sustained GH pulse amplitude; ghrelin pathway activation may increase appetite in some users
- MK-677 (Ibutamoren)
- Ghrelin mimetic. Oral GH secretagogue
- 10–25 mg daily oral
- 2.1–2.9 kg
- 1.3–1.9 kg
- Oral administration convenience; less dramatic fat loss than injectable peptides; common side effects include water retention and elevated fasting glucose
- Tesamorelin
- Synthetic GHRH analog (44 amino acids)
- 2 mg daily SC
- 1.8–2.4 kg
- FDA-approved specifically for HIV-associated lipodystrophy; preferentially targets visceral fat over subcutaneous fat; higher cost than sermorelin
- Exogenous GH (Somatropin)
- Direct GH replacement
- 0.3–0.6 mg daily SC
- 4.2–5.8 kg
- 2.8–3.6 kg
- Most dramatic body composition changes; suppresses endogenous GH production and carries highest risk of receptor downregulation, insulin resistance, and joint pain